HtrA1 and HtrA2 expression differentially modulate the clinical prognosis of cancer: a multi-omics analysis using bioinformatics approaches.

Abstract

Globally the second most common cause of human death is cancer. Cancer treatment is getting a satisfactory response, and molecular biomarkers are among the most important ways for this research. But still, all information is unavailable to detect cancer in the early stage, and the relation of groups of the gene with cancer has to explore. High-temperature requirement proteins HtrA1 and HtrA2 are serine proteases studied for therapeutic application and involvement in disease. HtrA1 and HtrA2 both belong to the HtrA serine protease family, but different studies explore their distinguishing role in cancer and neuro disease. The present study aimed to assess the expression pattern of HtrA1 and HtrA2 in different cancers and evaluate the prognostic outcome in cancer. Various bioinformatics databases and methodologies are used in this study, including Oncomine, KM plotter, OncoLnc, R2 platform, PrognoScan databases, GEPIA, cBioPortal, STRING, KEGG, and Reactome pathways analyses. We observed differential mRNA expression patterns of HtrA1 and HtrA2 genes in different cancers and differential survival pattern, mutation, copy number alteration of gene, gene ontology pathways in these genes. The HtrA1 gene shows a large difference in expression between cancer and normal tissues and could be prognostic biomarkers in particular cancer. Although HtrA2 showed consistent downregulation in different cancers, it could also be prognostic biomarkers in particular cancer. [ J Adv Biotechnol Exp Ther 2022; 5(2.000): 358-380]

Keywords

• cancer
• htra
• mrna
• mutation
• survival
• prognostic biomarkers
• multiomics
• bioinformatics
• cancer therapy